| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00261430: A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone. |
|
|
| Completed | 4 | 650 | US | GAIN Acceptance Approach | Janssen, LP | Schizophrenia | | 10/04 | | |
NCT00215579: Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence |
|
|
| Completed | 4 | 64 | US | Depot Risperidone Microsphere (Consta) | Duke University, Janssen, LP | Schizophrenia, Schizoaffective Disorder | 04/06 | 04/06 | | |
NCT00314613: Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal |
|
|
| Terminated | 4 | 30 | US | Antipsychotic/Risperidone Consta | Duke University, Janssen, LP | Schizophrenia | 12/06 | | | |
NCT00216528: A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres |
|
|
| Completed | 4 | 527 | RoW | risperidone | Janssen Korea, Ltd., Korea | Schizophrenia | | 04/07 | | |
NCT00216632: A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) |
|
|
| Completed | 4 | 99 | Europe | risperidone | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders | 07/07 | 07/07 | | |
NCT00369239: Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis |
|
|
| Completed | 4 | 303 | Europe | risperidone long acting injectable | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders, Schizoaffective Disorder | | 11/07 | | |
NCT00313391: Risperdal Consta and Health Care Utilization in Patients With Schizophrenia |
|
|
| Completed | 4 | | US | Risperdal Consta | Emory University, Janssen, L.P. - Investigator Initiated Studies Program | Schizophrenia, Schizoaffective Disorder | 12/07 | | | |
NCT01726335: Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia |
|
|
| Completed | 4 | 53 | RoW | Risperidone prolonged release, - Risperdal consta | Janssen-Cilag Ltd. | Schizophrenia | 03/08 | 03/08 | | |
NCT00246259: A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis |
|
|
| Completed | 4 | 77 | Canada | Risperidone long-acting injection (LAI), Oral Antipsychotic | Janssen-Ortho Inc., Canada | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders | 12/08 | 12/08 | | |
NCT00299702: Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia |
|
|
| Completed | 4 | 355 | US | Abilify, Risperidal Consta | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Psychotic Disorders | 01/09 | 01/09 | | |
NCT00526877: An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment |
|
|
| Completed | 4 | 31 | RoW | Risperidone, Risperdal Consta | Johnson & Johnson Taiwan Ltd | Schizophrenia, Schizoaffective Disorders | 01/09 | 01/09 | | |
| Completed | 4 | 50 | US | Risperdal (risperidone) Consta, Risperidone long-acting injectible, Treatment as usual, Usual care | Vanderbilt University, Ortho-McNeil Janssen Scientific Affairs, LLC | Bipolar Disorder | 02/09 | 02/09 | | |
NCT01855074: An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders |
|
|
| Completed | 4 | 80 | RoW | Risperidone | Janssen-Cilag Ltd. | Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder | 02/09 | 02/09 | | |
| Completed | 4 | 219 | US | Risperidone, Risperdal, Risperdal Consta, Olanzapine, Zyprexa, Ziprasidone, Geodon, Quetiapine, Seroquel, Aripiprazole, Abilify | Icahn School of Medicine at Mount Sinai, National Institute of Mental Health (NIMH) | Schizophrenia | 03/09 | 03/09 | | |
NCT00256997 / 2005-004383-23: A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication |
|
|
| Terminated | 4 | 167 | Canada, Europe, RoW | Risperidone long-acting injection (LAI), Oral atypical Antipsychotic | Janssen-Ortho Inc., Canada | Schizophrenia | 04/09 | 04/09 | | |
NCT00130923: Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder |
|
|
| Completed | 4 | 95 | US | Risperidone Long Acting, Risperdal Consta, oral risperidone, Risperdal | Dartmouth-Hitchcock Medical Center, Janssen, LP | Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse | 06/09 | 07/10 | | |
NCT00216671: Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode |
|
|
| Completed | 4 | 220 | Europe, RoW | early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta | Janssen Pharmaceutica N.V., Belgium | Schizophrenia | 12/09 | 12/09 | | |
2005-002304-41: Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode |
|
|
| Completed | 4 | 220 | Europe, RoW | RISPERDAL Consta/37,5mg, RISPERDAL Consta/50mg, RISPERDAL Quicklet/1mg, RISPERDAL Quicklet/2mg, RISPERDAL Quicklet/3mg, RISPERDAL Quicklet/4mg, Risperdal 1mg Tablets, Risperdal Consta/25 mg, F109, F555, F556, F146, F147, F5, Suspension for injection, Tablet, Risperdal Consta, Risperdal Quicklet | Janssen-Cilag EMEA Medical Affairs, Janssen-Cilag Medical Affairs EMEA, Janssen Cilag EMEA Medical Affairs, Janssen-Cilag EMEA | Schizophrenia | | | | |
NCT00378092 / 2015-001221-16: A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode |
|
|
| Completed | 4 | 33 | RoW | Oral risperidone, Risperidone Long-Acting Injection (RLAI), Risperdal consta | Janssen Cilag N.V./S.A. | Schizophrenia | 03/10 | 03/10 | | |
NCT00992407: An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 4 | 75 | RoW | Risperidone long acting injectables, Risperdal Consta, Risperidone tablets, Risperdal | Janssen Korea, Ltd., Korea | Schizophrenia | 12/10 | 12/10 | | |
PROACTIVE, NCT00330863: Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy |
|
|
| Completed | 4 | 357 | US | Risperidone microspheres, Risperdal Consta, Risperidone, Risperdal, Olanzapine, Zyprexa, Quetiapine, Seroquel, Ziprasidone, Geodon, Aripiprazole, Abilify, Paliperidone, Invega | Northwell Health, National Institute of Mental Health (NIMH) | Schizophrenia, Schizoaffective Disorder | 01/11 | 01/11 | | |
NCT00975611: Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation |
|
|
| Terminated | 4 | 6 | US | Amantadine Hydrochloride, USP, Symmetrel, Placebo, Symmetrel placebo | David C. Henderson, MD, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia, Schizoaffective Disorder | 01/12 | 01/12 | | |
NCT00539071: High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone |
|
|
| Completed | 4 | 160 | US | long-acting injectable risperidone, long acting injectable risperidone, Risperidone Consta | Northwestern University, Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia, Schizoaffective Disorder | 05/12 | 05/12 | | |
NCT00330551: Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia |
|
|
| Completed | 4 | 126 | US | Oral Risperidone, Risperdal, Risperidone in Long-Acting Injectable Form (Consta), Risperdal Consta | University of California, Los Angeles, National Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC | Schizophrenia | 11/12 | 11/12 | | |
NCT00333177: Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia |
|
|
| Completed | 4 | 92 | US | Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperdal, Risperidone, administered via injection (RLAI), Risperdal Consta | University of California, Los Angeles, National Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC | Schizophrenia | 01/13 | 01/13 | | |
| Terminated | 4 | 1 | US | long-acting injectable risperidone, Risperdal (oral) & Risperdal Consta | Northwell Health, The Zucker Hillside Hospital, National Alliance for Research on Schizophrenia and Depression | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified | 11/13 | 11/13 | | |
2004-004482-15: Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung. |
|
|
| Ongoing | 4 | 28 | Europe | Ziprasidon (Zeldox), Risperidon (Risperdal) Tablette, Risperidon (Risperdal) Lösung, Risperidon (Risperdal) Quicklet, Risperidon (Risperdal) Consta, Zeldox, Risperidon (Risperdal), Zeldox, Risperidon (Risperdal) | Universitätsklinikum Aachen, Klinik f. Psychiatrie und Psychotherapie | Patienten mit DSM-IVTR diagnostizierter Schizophrenie | | | | |
2005-004621-25: Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta? |
|
|
| | 4 | 40 | Europe | RISPERDAL Consta/25mg, RISPERDAL Consta/37,5mg, RISPERDAL Consta/50mg, Risperdal 1mg Tablets, F109, F5, RISPOLEPT CONSTA 25 mg, RISPOLEPT CONSTA 37.5 mg, RISPOLEPT CONSTA 50 mg, RISPOLEPT 1 mg, RISPOLEPT CONSTA 25 mg, RISPOLEPT CONSTA 37.5 mg, RISPOLEPT CONSTA 50 mg, RISPOLEPT 1 mg | Janssen-Cilag Medical Affairs EMEA, Janssen-Cilag B.V., Janssen-Cilag EMEA, Janssen Cilag EMEA, JANSSEN-CILAG EMEA, Janssen-Cilag International N.V., Janssen-Cilag Ltd | Schizophrenia, schizoaffective disorder | | 10/07 | | |
NCT02472652: Aripiprazole, Abilify Maintena Collaborative Clinical Protocol |
|
|
| Terminated | 4 | 2 | US | Abilify Maintena, Aripiprazole | Gazda, Thomas D., M.D., PC, Otsuka America Pharmaceutical | Sexual Dysfunction | 12/16 | 03/17 | | |
2004-000870-29: CONSTATRERisperdal Consta Trial of Relapse Prevention and Effectiveness |
|
|
| | 3/4 | 200 | Europe | Risperdal Consta 25mg, Risperdal Consta 37.5mg, Risperdal Consta 50mg, Risperdal Quicklet 1mg, Risperdal Quicklet 2mg, Aripiprazole 10 mg, Aripiprazole 15 mg, Aripiprazole 30 mg, Quetiapine 25mg, Quetiapine 100mg, Quetiapine 200mg, F109, F555, F556, Risperdal Consta, Risperdal Quicklet, Abilify, Seroquel, Risperdal Consta, Risperdal Quicklet, Abilify, Seroquel | Janssen-Cilag Medical Affairs EMEA, Janssen-Cilag,S.A., JANSSEN-CILAG | SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER | | 11/07 | | |
